12,372 trials
Warm Antibody Autoimmune Hemolytic Anemia
Primary: Durable Hemoglobin Response — 16; 12 Participants
Acute Myeloid Leukemia
Primary: Overall Survival — 191.0; 163.0 days — p== 0.3287
Pain, Post-operative
Primary: Number of Subjects With Adverse Events — 339; 119 Participants
Pain, Postoperative
Primary: Opioid Use Hour 0-24 — 18.94; 27.73 mg morphine equivalent
Factor VIII Deficiency
Primary: Estimated Annualized Bleeding Rate (ABR) in Arm A: Prophylaxis — 0.71 episodes per participant per year
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -2.03; -1.08 Percentage of HbA1c — p=<0.001
Out-Of-Hospital Cardiac Arrest
Primary: Number of Participants Who Survived to Hospital Admission — 218; 205; 212 Participants — p=0.82
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Primary: Epoch 1: Relapse Rate — 31.4; 9.7 percentage of participants — p==0.0045
Chronic Migraine
Primary: Number of Participants With Adverse Events — 1 Participants
Spinal Cord Injury
Primary: Change in Areal Bone Mineral Density at Hip — 0.92; -12.0; 1.19; -12.9 percentage change
Primary Myelofibrosis (PMF) · Post-polycythemia Vera (Post-PV) · Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Primary: Splenic Response Rate at Week 24 — 7; 3; 97; 49 Participants — p=0.90
Leptin Receptor Deficiency Obesity
Primary: Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) — 45.5 percentage of participants — p=0.0001
Paroxysmal Nocturnal Hemoglobinuria
Primary: LDH Level at Week 27 (Parallel Comparison) — 205.69; 193.53 U/L
Congenital Heart Defect
Primary: Length of Hospital Stay Following Fontan — 11.2; 11 days
Primary Axillary Hyperhidrosis
Primary: The Number of Participants With Treatment Emergent Adverse Events Cumulative to Week 48 by Maximum Severity — 27; 55; 29; 58 Participants